Clinical trials: HNSCC
HNSCC
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
This is a Phase II single-arm window trial to assess the clinical and biological effects of neoadjuvant abemaciclib in patients with HPV-negative head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT04169074
- Testing
- Abemaciclib
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Arizona
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
There is a significant unmet medical need for effective therapies for pediatric relapsed/refractory solid tumors. EGFR is highly and stably expressed in multiple pediatric solid tumor subtypes, and adult Phase I data of Becotatug…
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
- Trial name
- MRG003 (NCT07584499)
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
HNSCC, AI
10-year Retrospective Study of Oral and Maxillofacial Squamous Cell Carcinoma
Introduction: The incidence of occult cervical lymph node metastases (OCLNM) is reported to be 20%-30% in early-stage oral cancer and oropharyngeal cancer.
- Conditions
- HNSCC, AI, Radiomic, MRI
- Trial name
- NCT06366906
- Testing
- The Resnet50 deep learning (DL) model
- Where
- 2 sites in China
- Volunteers
- 319 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University